On the whole, these data suggest that the addition of PRKDC inhibitors to classic chemotherapy might be beneficial for a high percentage of CRC patients, mainly because potent PRKDC inhibitors (AZD7648, nedisertib) are currently entering early clinical trials. This evidence concerns the gene PRKDC and colorectal carcinoma.